Clinical trial

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

NCT01921335

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-08-01

PhasePHASE1

Study timeline

Study start (actual)2013-08-01Date precision: month

Registry last updated2024-11-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Brain Metastases From HER2 and Breast Cancerunresolved

Advanced HER2-positive Breast Cancerunresolved

Interventions

ARRY-380 Twice Daily DosageDRUG

ARRY-380 Once DailyDRUG

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Array BioPharmacollaborator

Breast Cancer Research Foundationcollaborator

Mapped research locations

BostonMassachusetts, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01921335 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.